A Phase 2 interventional study of WAS123 and Aripiprazole (Fixed dose) in Schizophenia Disorder, sponsored by EMS. Completed at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by EMS · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Schizophrenia with a site in Brazil — 3 open to participants now, 3 under way, 2 of them phase 3. Schizophrenia · Brazil.
Among the 61 studies in Schizophrenia with a site in Brazil, this one is the 34th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2022, is one of 9 in phase 2, and was the 61st registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →3 of the 61 studies in Schizophrenia with a site in Brazil are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Brazil, United States, Argentina and 4 more countries
Ages 18–55
Alkermes, Inc. · Sites in Brazil, United States, Argentina and 2 more countries
Ages 10–17
Alkermes, Inc. · Sites in Brazil, United States, Argentina and 2 more countries
Ages 10–17
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 27 · Phase 4 12
First in 2001; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 163 across the 57 interventional studies, 310 across the 3 observational. Of the 49 that completed or were terminated, 17 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 61 have an industry lead sponsor. The 10 most frequent:
EMS is the lead sponsor of 84 studies on the registry; 21 are open to participants now.
EMS has 1 study filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
2 of the studies in Schizophrenia with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04987229Phase 3Alkermes, Inc.Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects | 2027-09 |
| NCT07410507Eli Lilly and CompanyA Study of Brenipatide in Adult Participants With Schizophrenia | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 61 studies in Schizophrenia with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase II, proof-of-concept, national, multicenter, randomized, double-blind clinical trial to compare the efficacy and safety of WAS123 in the maintenance treatment of patients with schizophrenia, with a parallel design between 2 groups and controlled by an active comparator (Aripiprazole).
A total of 121 participants were randomized and assigned to either 1 of 2 treatment groups in a 1:1 ratio.
Aripiprazole is an atypical antipsychotic for the maintenance treatment of acute and chronic schizophrenia and bipolar 1 disorder in adults. This was a phase II, proof-of-concept, national, multicenter, randomized, double-blind clinical trial to compare the efficacy and safety of WAS123 in the maintenance treatment of patients with schizophrenia, with a parallel design between 2 groups and controlled by an active comparator (Aripiprazole).
Primary Objective: To evaluate the non-inferiority in efficacy of the WAS123 compared to the dosage of Aripiprazole in the overall symptomatic control of participants with schizophrenia.
Methodology: A total of 121 participants were randomized, and assigned to 1 of the 2 treatment arms of the trial in a 1:1 ratio.
This was a double-blind trial, no participant or person involved in its conduct, including those people responsible for data management, were aware of the allocation of treatments to participants.
Diagnosis and Main Criteria for Inclusion and Exclusion: The trial target population was made up of adults of both sexes aged 18 or over and 65 or under diagnosed with schizophrenia according to the DSM-5 diagnostic criteria. Participants were ineligible if they had another psychiatric disorder with psychotic symptoms other than schizophrenia or with schizophrenia refractory or resistant to antipsychotic treatment.
Duration of Treatment: The treatment period for the trial consisted of a mandatory 8-week (56-day) run-in for symptom stabilization, followed by randomization and 12 weeks (90 days) of treatment with the trial medications , totaling 20 weeks.
Statistical Methods:
The primary endpoint was analyzed using a generalized linear model including treatment effect and baseline as covariate and parameters were estimated by maximum likelihood. The treatment effect was expressed as the difference between the trial medication and the comparator, and a 95% confidence interval (CI) for this difference was calculated. Non-inferiority was concluded if the upper limit of the 95% CI was less than the pre-specified non-inferiority margin. As a sensitivity analysis, the same model was applied to data from the mITT set.
AEs, diseases, and comorbidities were coded using MedDRA. Safety analyses were descriptive and summarized vital signs, clinical, laboratory, and physical examination findings, as well as all AEs. AE frequencies were presented by treatment group according to causality, intensity, frequency, and severity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of schizophrenia according to diagnostic criteria and who:
At Screening:
At randomization:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
oral dose
Drug: WAS123
oral daily dose
Drug: Aripiprazole (Fixed dose)
oral dose
oral daily dose
Score PANSS
To evaluate the non-inferiority in efficacy of the WAS123 compared to the dosage of Aripiprazole in the overall symptomatic control of participants with schizophrenia.
Time frame: From enrollment to the end of treatment at 12 weeks
Plan to share: Yes — Deidentified individual participant data that support the reported results may be made available upon reasonable request and subject to Sponsor review and approval, after publication of the primary study results.
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Jan 2026, 44 months.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 44 months is above that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.